PDF(Pubmed)
Abstract：
We aimed to describe baseline amyloid-beta (Aβ) and tau-positron emission tomograrphy (PET) from Longitudinal Early-onset Alzheimer\'s Disease Study (LEADS), a prospective multi-site observational study of sporadic early-onset Alzheimer\'s disease (EOAD).
We analyzed baseline [18F]Florbetaben (Aβ) and [18F]Flortaucipir (tau)-PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aβ+) from EOnonAD (Aβ-) based on the combination of visual read by expert reader and image quantification.
243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid-PET; 231 (95.1%) of them were tau-PET positive (A+T+). Tau-PET signal was elevated across cortical regions with a parietal-predominant pattern, and higher burden was observed in younger and female EOAD participants.
LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau-PET binding at baseline might have implications for therapeutic strategies in patients with EOAD.
72% of patients with clinical EOAD were positive on both amyloid- and tau-PET. Amyloid-positive patients with EOAD had high tau-PET signal across cortical regions. In EOAD, tau-PET mediated the relationship between amyloid-PET and MMSE. Among EOAD patients, younger onset and female sex were associated with higher tau-PET.
We analyzed baseline [18F]Florbetaben (Aβ) and [18F]Flortaucipir (tau)-PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aβ+) from EOnonAD (Aβ-) based on the combination of visual read by expert reader and image quantification.
243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid-PET; 231 (95.1%) of them were tau-PET positive (A+T+). Tau-PET signal was elevated across cortical regions with a parietal-predominant pattern, and higher burden was observed in younger and female EOAD participants.
LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau-PET binding at baseline might have implications for therapeutic strategies in patients with EOAD.
72% of patients with clinical EOAD were positive on both amyloid- and tau-PET. Amyloid-positive patients with EOAD had high tau-PET signal across cortical regions. In EOAD, tau-PET mediated the relationship between amyloid-PET and MMSE. Among EOAD patients, younger onset and female sex were associated with higher tau-PET.
摘要：
背景：我们旨在描述纵向早发性阿尔茨海默病研究（LEADS）的基线β淀粉样蛋白（Aβ）和tau-正电子发射断层扫描（PET），一项对散发性早发性阿尔茨海默病（EOAD）的前瞻性多地点观察性研究。
方法：我们分析了基线[18F]Florbetaben(Aβ)和[18F]Flortaucipir(tau)-PET，这些受试者的临床诊断为轻度认知障碍(MCI)或年龄<65岁的AD痴呆。基于专家读者的视觉阅读和图像量化的结合，使用Florbetaben扫描来区分EOAD（Aβ）和EOnonAD（Aβ-）的认知障碍参与者。
结果：243/321（75.7％）的参与者根据淀粉样蛋白PET被分配到EOAD组；其中231（95.1％）的tau-PET阳性（AT）。Tau-PET信号在皮层区域以顶叶为主的模式升高，在年轻和女性EOAD参与者中观察到更高的负担。
结论：LEADS数据强调了生物标志物对提高EOAD诊断准确性的重要性。基线时的高级tau-PET结合可能对EOAD患者的治疗策略有影响。
结论：72%的临床EOAD患者淀粉样蛋白和tau-PET均为阳性。患有EOAD的淀粉样蛋白阳性患者在皮质区域具有高tau-PET信号。在EOAD中,tau-PET介导淀粉样蛋白PET与MMSE之间的关系。在EOAD患者中，较年轻的发病和女性性别与较高的tau-PET相关.
方法：我们分析了基线[18F]Florbetaben(Aβ)和[18F]Flortaucipir(tau)-PET，这些受试者的临床诊断为轻度认知障碍(MCI)或年龄<65岁的AD痴呆。基于专家读者的视觉阅读和图像量化的结合，使用Florbetaben扫描来区分EOAD（Aβ）和EOnonAD（Aβ-）的认知障碍参与者。
结果：243/321（75.7％）的参与者根据淀粉样蛋白PET被分配到EOAD组；其中231（95.1％）的tau-PET阳性（AT）。Tau-PET信号在皮层区域以顶叶为主的模式升高，在年轻和女性EOAD参与者中观察到更高的负担。
结论：LEADS数据强调了生物标志物对提高EOAD诊断准确性的重要性。基线时的高级tau-PET结合可能对EOAD患者的治疗策略有影响。
结论：72%的临床EOAD患者淀粉样蛋白和tau-PET均为阳性。患有EOAD的淀粉样蛋白阳性患者在皮质区域具有高tau-PET信号。在EOAD中,tau-PET介导淀粉样蛋白PET与MMSE之间的关系。在EOAD患者中，较年轻的发病和女性性别与较高的tau-PET相关.
